Muriel Picard
Overview
Explore the profile of Muriel Picard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
296
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Duvaltier L, Joher N, Argaud L, Guillon A, Picard M, Canet E, et al.
Am J Respir Crit Care Med
. 2024 Oct;
210(12):1483-1486.
PMID: 39441138
No abstract available.
2.
Lafarge A, Dupont T, Canet E, Moreau A, Picard M, Mokart D, et al.
Am J Respir Crit Care Med
. 2024 Jul;
210(8):1017-1024.
PMID: 39018219
Allogeneic hematopoietic stem-cell transplantation (Allo-HSCT) recipients are still believed to be poor candidates for ICU management. We investigated outcomes and determinants of mortality in a large multicenter retrospective cohort of...
3.
Demonchy J, Biard L, Clere-Jehl R, Wallet F, Mokart D, Moreau A, et al.
Emerg Infect Dis
. 2024 Jan;
30(2).
PMID: 38270146
Invasive fusariosis can be life-threatening, especially in immunocompromised patients who require intensive care unit (ICU) admission. We conducted a multicenter retrospective study to describe clinical and biologic characteristics, patient outcomes,...
4.
Arrestier R, Chaba A, Mabrouki A, Saccheri C, Canet E, De Chambrun M, et al.
Ann Intensive Care
. 2023 Apr;
13(1):34.
PMID: 37115415
Background: Necrotizing soft tissue infections (NSTIs) are rare life-threatening bacterial infections. Few data are available regarding neutropenic patients with NSTIs. Our objectives were to describe the characteristics and management of...
5.
Sabatier M, Birsen R, Lauture L, Mouche S, Angelino P, Dehairs J, et al.
Cancer Discov
. 2023 Apr;
13(7):1720-1747.
PMID: 37012202
Significance: FLT3 mutations are found in 30% of AML cases and are actionable by tyrosine kinase inhibitors. Here, we discovered that C/EBPα regulates FA biosynthesis and protection from lipid redox...
6.
Meert A, Toffart A, Picard M, Jaubert P, Gibelin A, Bauer P, et al.
Bull Cancer
. 2023 Feb;
110(4):467-468.
PMID: 36805208
No abstract available.
7.
Navarro A, Gomez C, Angeles M, Fuzier R, Ruiz J, Picard M, et al.
Gynecol Oncol
. 2023 Jan;
170:108-113.
PMID: 36681011
Introduction: The aim of this study was to evaluate the indications and management of grade III-IV postoperative complications in patients requiring vacuum-assisted open abdomen after debulking surgery for ovarian carcinomatosis....
8.
Canali A, Vergnolle I, Bertoli S, Largeaud L, Nicolau M, Rieu J, et al.
Clin Cancer Res
. 2022 Nov;
29(1):134-142.
PMID: 36318706
Purpose: Acute myeloid leukemias (AML) are clonal diseases that develop from leukemic stem cells (LSC) that carry an independent prognostic impact on the initial response to induction chemotherapy, demonstrating the...
9.
Vergez F, Largeaud L, Bertoli S, Nicolau M, Rieu J, Vergnolle I, et al.
Blood Cancer J
. 2022 Aug;
12(8):117.
PMID: 35973983
Classifications of acute myeloid leukemia (AML) patients rely on morphologic, cytogenetic, and molecular features. Here we have established a novel flow cytometry-based immunophenotypic stratification showing that AML blasts are blocked...
10.
Rieu J, Coster L, Corre J, Tavitian S, Recher C, Huynh A, et al.
EJHaem
. 2022 Jul;
1(2):589-592.
PMID: 35845019
No abstract available.